Regardless, one uniqueness of our studies is the demonstration that TET2 is an important contributor to acquired sorafenib resistance, because TET2 is significantly upregulated in sorafenibR HCC cells, and a poorer survival is noticed in sorafenib-treated HCC patients overexpressing TET2. This evidence concerns the gene TET2 and hepatocellular carcinoma.